Publications by authors named "Carl Ruby"

Claim this Profile
C
Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast.
Kartikeya Vijayasimha, Andrew J Annalora, Dan V Mourich, Carl E Ruby, Brian P Dolan

Vet Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology.
Jeilene N Hambly, Carl E Ruby, Dan V Mourich, Shay Bracha, Brian P Dolan

Vet Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creating a Selective Nanobody Against 3-Nitrotyrosine Containing Proteins.
Elise M Van Fossen, Sonia Grutzius, Carl E Ruby, Dan V Mourich, Chris Cebra

Front Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma.
Marcus A Weinman, Stephen A Ramsey, Haley J Leeper, Jacqueline V Brady, Andrew Schlueter, Carl E Ruby

Cancer Cell Int· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fasting reduces the incidence of vincristine-associated adverse events in dogs.
Margaret E Duckett, Kaitlin M Curran, Haley J Leeper, Carl E Ruby, Shay Bracha

Vet Comp Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Preliminary Proteomic Investigation of Circulating Exosomes and Discovery of Biomarkers Associated with the Progression of Osteosarcoma in a Clinical Model of Spontaneous Disease.
Jacqueline V Brady, Ryan M Troyer, Stephen A Ramsey, Haley Leeper, Liping Yang, Carl E Ruby

Transl Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells.
Ryan M Troyer, Carl E Ruby, Cheri P Goodall, Liping Yang, Claudia S Maier

Exp Cell Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virus therapy for cancer.
Joe Goldufsky, Shanthi Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Carl E Ruby

Oncolytic Virother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Sanja B Turturro, Matthew S Najor, Carl E Ruby, Melody A Cobleigh, Abde M Abukhdeir

Breast Cancer Res Treat· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.
Frederick J Kohlhapp, Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Jevgenijs Lusciks, Carl E Ruby

J Immunother Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.
Joe Goldufsky, Stephen Wood, Behnam Hajihossainlou, Tooba Rehman, Omar Majdobeh, Carl E Ruby

J Med Microbiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Michelle E Doscas, Ashley J Williamson, Lydia Usha, Yedida Bogachkov, Geetha S Rao, Carl Ruby

Neoplasia· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming.
Michelle Farazi, Zachary Cohn, Justine Nguyen, Andrew D Weinberg, Carl E Ruby

J Leukoc Biol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging.
Michelle Farazi, Justine Nguyen, Josef Goldufsky, Stephanie Linnane, Lisa Lukaesko, Carl E Ruby

Cancer Immunol Immunother· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Howard L Kaufman, Carl E Ruby, Tasha Hughes, Craig L Slingluff

J Immunother Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.
Dae Won Kim, Andrew Zloza, Joseph Broucek, Jason M Schenkel, Carl Ruby

J Transl Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal management of metastatic melanoma: current strategies and future directions.
Marta Batus, Salman Waheed, Carl Ruby, Lindsay Petersen, Steven D Bines

Am J Clin Dermatol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TroVax(®) vaccine therapy for renal cell carcinoma.
Rui-Tao Zhang, Steven D Bines, Carl Ruby, Howard L Kaufman

Immunotherapy· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.
Nicole A Vasilevsky, Carl E Ruby, Peter J Hurlin, Andrew D Weinberg

Eur J Immunol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling through OX40 enhances antitumor immunity.
Shawn M Jensen, Levi D Maston, Michael J Gough, Carl E Ruby, William L Redmond

Semin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Carl E Ruby, Andrew D Weinberg

Cancer Immunol Immunother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of aging on cancer immunity and immunotherapy.
Graham Pawelec, Joseph Lustgarten, Carl Ruby, Claudia Gravekamp

Cancer Immunol Immunother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
Carl E Ruby, Melissa A Yates, Daniel Hirschhorn-Cymerman, Peter Chlebeck, Jedd D Wolchok

J Immunol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of OX40-mediated co-stimulation in T-cell activation and survival.
William L Redmond, Carl E Ruby, Andrew D Weinberg

Crit Rev Immunol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40-enhanced tumor rejection and effector T cell differentiation decreases with age.
Carl E Ruby, Andrew D Weinberg

J Immunol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis